# Budget Impact Analysis for Empagliflozin in Patients with Nondiabetic CKD

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/budget-impact-analysis-for-empagliflozin-in-patients-with-nondiabetic-ckd/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Satabdi Chatterjee,Neda Al Rawashdh,Pablo Anaya,A. Uster,Anna Mazo,Mafalda Ramos,Laetitia Gerlier,Mark Lamotte |
| Citations | 0 |
| DOI | 10.1681/asn.2024qt974p29 |
| Fields | Economics, Econometrics and Finance |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4403831738 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Satabdi Chatterjee](https://scholariq.org/researchers/satabdi-chatterjee/)
- [Anna Mazo](https://scholariq.org/researchers/anna-mazo/)

## Paper journal

- [Journal of the American Society of Nephrology](https://scholariq.org/journals/journal-of-the-american-society-of-nephrology/)

## Paper primary topic

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Paper topics

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Pharmaceutical Economics and Policy](https://scholariq.org/topics/pharmaceutical-economics-and-policy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.